{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:46:58Z","timestamp":1792583218770,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03635-3","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:31:43Z","timestamp":1792582303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Spatial transcriptomic sequencing identifies lipid metabolism and mitochondrial respiration as central features of T cell excluded esophageal adenocarcinomas"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9521-0557","authenticated-orcid":false,"given":"Jasper","family":"Sanders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma N.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3460-3320","authenticated-orcid":false,"given":"Deni M.","family":"van Schie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac J.","family":"Nijman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-0760","authenticated-orcid":false,"given":"Nicole C. T.","family":"van Grieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"van der Peet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Grootjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten F.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7852-2891","authenticated-orcid":false,"given":"Jan","family":"Van den Bossche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-7457","authenticated-orcid":false,"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"3635_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3635_CR2","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/0284186X.2020.1870246","volume":"60","author":"A Al-Kaabi","year":"2021","unstructured":"Al-Kaabi A, van der Post RS, van der Werf LR, Wijnhoven BPL, Rosman C, Hulshof MCCM, et al. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study. Acta Oncol. 2021;60:497\u2013504.","journal-title":"Acta Oncol"},{"key":"3635_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae034","volume":"111","author":"SPG Henckens","year":"2024","unstructured":"Henckens SPG, Liu D, Gisbertz SS, Kalff MC, Anderegg MCJ, Crull D, et al. Prognostic value of Mandard score and nodal status for recurrence patterns and survival after multimodal treatment of oesophageal adenocarcinoma. Br J Surg. 2024;111:znae034. https:\/\/doi.org\/10.1093\/bjs\/znae034.","journal-title":"Br J Surg"},{"key":"3635_CR4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203.","journal-title":"N Engl J Med"},{"key":"3635_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. Nivolumab plus chemotherapy versus chemotherapy as first line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/oesophageal adenocarcinoma (CheckMate 649): a multicentre, randomised, open-label, phase 3 trial HHS Public Access. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"3635_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"3635_CR7","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-19-0908","volume":"25","author":"SC Kamran","year":"2019","unstructured":"Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, et al. Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer. Clin Cancer Res. 2019;25:5561\u201371.","journal-title":"Clin Cancer Res"},{"key":"3635_CR8","doi-asserted-by":"crossref","unstructured":"Goedegebuure RSA, Harrasser M, de Klerk LK, van Schooten TS, van Grieken NCT, Eken M, et al. Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma. Oncoimmunology. 2021;10:1954807.","DOI":"10.1080\/2162402X.2021.1954807"},{"key":"3635_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.annonc.2020.04.011","volume":"31","author":"S Derks","year":"2020","unstructured":"Derks S, de Klerk LK, Xu X, Fleitas T, Liu KX, Liu Y, et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann Oncol. 2020;31:1011\u201320.","journal-title":"Ann Oncol"},{"key":"3635_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/cas.14328","volume":"111","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, Makino T, Sato E, Noma T, Urakawa S, Takeoka T, et al. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer. Cancer Sci. 2020;111:1103\u201312.","journal-title":"Cancer Sci"},{"key":"3635_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.ccell.2023.06.006","volume":"41","author":"TM Carroll","year":"2023","unstructured":"Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, et al. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma. Cancer Cell. 2023;41:1222\u2013.e7.","journal-title":"Cancer Cell"},{"key":"3635_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/2326-6066.CIR-15-0046","volume":"3","author":"S Derks","year":"2015","unstructured":"Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, et al. Epithelial PD-L2 expression marks Barrett\u2019s esophagus and esophageal Adenocarcinoma. Cancer Immunol Res. 2015;3:1123\u20139.","journal-title":"Cancer Immunol Res"},{"key":"3635_CR13","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/b-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25:3074\u201383.","journal-title":"Clin Cancer Res"},{"key":"3635_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Gro\u00df O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11:5439.","journal-title":"Nat Commun"},{"key":"3635_CR15","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355:1979.","journal-title":"Science"},{"key":"3635_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR Merritt","year":"2020","unstructured":"Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38:586\u201399.","journal-title":"Nat Biotechnol"},{"key":"3635_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28020-5","volume":"13","author":"P Danaher","year":"2022","unstructured":"Danaher P, Kim Y, Nelson B, Griswold M, Yang Z, Piazza E, et al. Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data. Nat Commun. 2022;13:385.","journal-title":"Nat Commun"},{"key":"3635_CR18","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20138.","journal-title":"Nat Med"},{"key":"3635_CR19","doi-asserted-by":"publisher","first-page":"100802","DOI":"10.1016\/j.xcrm.2022.100802","volume":"3","author":"MPG Dings","year":"2022","unstructured":"Dings MPG, van der Zalm AP, Bootsma S, van Maanen TFJ, Waasdorp C, van den Ende T, et al. Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. Cell Rep Med. 2022;3:100802.","journal-title":"Cell Rep Med"},{"key":"3635_CR20","doi-asserted-by":"crossref","unstructured":"Shao F, Mao H, Luo T, Li Q, Xu L, Xie Y. HPGDS is a novel prognostic marker associated with lipid metabolism and aggressiveness in lung adenocarcinoma. Front Oncol. 2022;12:894485.","DOI":"10.3389\/fonc.2022.894485"},{"key":"3635_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2004.09.037","volume":"119","author":"BM Spiegelman","year":"2004","unstructured":"Spiegelman BM, Heinrich R. Biological control through regulated transcriptional coactivators. Cell. 2004;119:157\u201367.","journal-title":"Cell"},{"key":"3635_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/jcmm.17191","volume":"26","author":"ZW Liang","year":"2022","unstructured":"Liang ZW, Yu J, Gu DM, Liu XM, Liu J, Wu MY, et al. M2-phenotype tumour-associated macrophages upregulate the expression of prognostic predictors MMP14 and INHBA in pancreatic cancer. J Cell Mol Med. 2022;26:1540\u201355.","journal-title":"J Cell Mol Med"},{"key":"3635_CR23","doi-asserted-by":"crossref","unstructured":"Ji P, Gong Y, Jin M, Wu H, Guo LW, Pei YC, et al. In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Sci Adv. 2022;8:eabl8247.","DOI":"10.1126\/sciadv.abl8247"},{"key":"3635_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11307-015-0882-0","volume":"18","author":"NA Jager","year":"2016","unstructured":"Jager NA, Wallis de Vries BM, Hillebrands JL, Harlaar NJ, Tio RA, Slart RHJA, et al. Distribution of matrix metalloproteinases in human atherosclerotic carotid plaques and their production by smooth muscle cells and macrophage subsets. Mol Imaging Biol. 2016;18:283\u201391.","journal-title":"Mol Imaging Biol"},{"key":"3635_CR25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cmet.2020.11.007","volume":"32","author":"RJ Arg\u00fcello","year":"2020","unstructured":"Arg\u00fcello RJ, Combes AJ, Char R, Gigan JP, Baaziz AI, Bousiquot E, et al. SCENITH: a flow cytometry-based method to functionally profile energy metabolism with single-cell resolution. Cell Metab. 2020;32:1063\u201375.","journal-title":"Cell Metab"},{"key":"3635_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32570-z","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Jia K, Sun Y, Zhang C, Li Y, Zhang L, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun. 2022;13:4851.","journal-title":"Nat Commun"},{"key":"3635_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nri.2016.70","volume":"16","author":"LAJ O'Neill","year":"2016","unstructured":"O'Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553\u201365.","journal-title":"Nat Rev Immunol"},{"key":"3635_CR28","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu S, Chaudhary O, Rodr\u00edguez-Morales P, Sun X, Chen D, Zappasodi R, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity. 2021;54:1561\u2013.e7.","journal-title":"Immunity"},{"key":"3635_CR29","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","volume":"186","author":"RD Michalek","year":"2011","unstructured":"Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol. 2011;186:3299\u2013303.","journal-title":"J Immunol"},{"key":"3635_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41590-019-0589-5","volume":"21","author":"H Wang","year":"2020","unstructured":"Wang H, Franco F, Tsui YC, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21:298\u2013308.","journal-title":"Nat Immunol"},{"key":"3635_CR31","doi-asserted-by":"crossref","unstructured":"Howie, D SP, Cobbold E, Adams A, Ten Bokum AS Necula, Zhang W, Huang H, et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight. 2017;2:e89160.","DOI":"10.1172\/jci.insight.89160"},{"key":"3635_CR32","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.4049\/jimmunol.1402469","volume":"194","author":"Z Tan","year":"2015","unstructured":"Tan Z, Xie N, Cui H, Moellering DR, Abraham E, Thannickal VJ, et al. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. J Immunol. 2015;194:6082\u20139.","journal-title":"J Immunol"},{"key":"3635_CR33","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.celrep.2016.09.008","volume":"17","author":"J Van\u00a0den\u00a0Bossche","year":"2016","unstructured":"Van\u00a0den\u00a0Bossche J, Baardman J, Otto NA, van\u00a0der\u00a0Velden S, Neele AE, van\u00a0den\u00a0Berg SM, et al. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep. 2016;17:684\u201396.","journal-title":"Cell Rep"},{"key":"3635_CR34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ni.2956","volume":"15","author":"SCC Huang","year":"2014","unstructured":"Huang SCC, Everts B, Ivanova Y, O'Sullivan D, Nascimento M, Smith AM, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol. 2014;15:846\u201355.","journal-title":"Nat Immunol"},{"key":"3635_CR35","doi-asserted-by":"publisher","first-page":"EMMM201910698","DOI":"10.15252\/emmm.201910698","volume":"11","author":"H Wu","year":"2019","unstructured":"Wu H, Han Y, Rodriguez Sillke Y, Deng H, Siddiqui S, Treese C, et al. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol Med. 2019;11:EMMM201910698.","journal-title":"EMBO Mol Med"},{"key":"3635_CR36","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1016\/j.cell.2024.07.030","volume":"187","author":"DJ Kloosterman","year":"2024","unstructured":"Kloosterman DJ, Erbani J, Boon M, Farber M, Handgraaf SM, Ando-Kuri M, et al. Macrophage-mediated myelin recycling fuels brain cancer malignancy. Cell. 2024;187:5336\u2013.e30.","journal-title":"Cell"},{"key":"3635_CR37","doi-asserted-by":"crossref","unstructured":"Tao X, Tao R, Wang K, Wu L. Anti-inflammatory mechanism of Apolipoprotein A-I. Front Immunol. 2024;15:1417270.","DOI":"10.3389\/fimmu.2024.1417270"},{"key":"3635_CR38","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.bbrc.2005.10.065","volume":"338","author":"KD Kim","year":"2005","unstructured":"Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I, et al. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun. 2005;338:1126\u201336.","journal-title":"Biochem Biophys Res Commun"},{"key":"3635_CR39","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.cmet.2019.02.016","volume":"29","author":"P Goossens","year":"2019","unstructured":"Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gouirand V, et al. Membrane Cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019;29:1376\u2013.e4.","journal-title":"Cell Metab"},{"key":"3635_CR40","doi-asserted-by":"crossref","unstructured":"Atehortua L, Davidson WS, Chougnet CA. Interactions between HDL and CD4+ T cells: a novel understanding of HDL anti-inflammatory properties. 2024;44:1191\u2013201.","DOI":"10.1161\/ATVBAHA.124.320851"},{"key":"3635_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cmet.2019.04.002","volume":"30","author":"X Ma","year":"2019","unstructured":"Ma X, Bi E, Lu Y, Su P, Huang C, Liu L, et al. Cholesterol induces CD8+ T cell exhaustion in the tumor microenvironment. Cell Metab. 2019;30:143\u2013.e5.","journal-title":"Cell Metab"},{"key":"3635_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49495-4","volume":"15","author":"ZX Yan","year":"2024","unstructured":"Yan ZX, Dong Y, Qiao N, Zhang YL, Wu W, Zhu Y, et al. Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. Nat Commun. 2024;15:5183.","journal-title":"Nat Commun"},{"key":"3635_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cmet.2017.11.001","volume":"27","author":"T Wang","year":"2018","unstructured":"Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, et al. JAK\/STAT3-regulated fatty acid \u03b2-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab. 2018;27:136\u2013.e5.","journal-title":"Cell Metab"},{"key":"3635_CR44","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.18632\/oncotarget.6757","volume":"7","author":"H Shao","year":"2016","unstructured":"Shao H, Mohamed EM, Xu GG, Waters M, Jing K, Ma Y, et al. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. 2016;7:3832\u201346.","journal-title":"Oncotarget"},{"key":"3635_CR45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.cmet.2017.09.006","volume":"26","author":"S Andrzejewski","year":"2017","unstructured":"Andrzejewski S, Klimcakova E, Johnson RM, Tabari\u00e8s S, Annis MG, McGuirk S, et al. PGC-1\u03b1 promotes breast cancer metastasis and confers bioenergetic flexibility against metabolic drugs. Cell Metab. 2017;26:778\u201387.","journal-title":"Cell Metab"},{"key":"3635_CR46","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/ncb3039","volume":"16","author":"VS Lebleu","year":"2014","unstructured":"Lebleu VS, O\u2019Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1\u03b1 mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16:992\u20131003.","journal-title":"Nat Cell Biol"},{"key":"3635_CR47","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716\u201335.","journal-title":"Cancer Discov"},{"key":"3635_CR48","doi-asserted-by":"crossref","unstructured":"Liu Z, Liu W, Wang W, Ma Y, Wang Y, Drum DL, et al. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing. Proc Natl Acad Sci USA. 2023;120:e2302878120.","DOI":"10.1073\/pnas.2302878120"},{"key":"3635_CR49","doi-asserted-by":"crossref","unstructured":"Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, et al. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019;4:e124989.","DOI":"10.1172\/jci.insight.124989"},{"key":"3635_CR50","doi-asserted-by":"crossref","unstructured":"Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife. 2020;9:e55185.","DOI":"10.7554\/eLife.55185"},{"key":"3635_CR51","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping NE, Menk AV, Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity. 2016;45:374\u201388.","journal-title":"Immunity"},{"key":"3635_CR52","doi-asserted-by":"crossref","unstructured":"Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol. 2019:10:1337.","DOI":"10.3389\/fimmu.2019.01337"},{"key":"3635_CR53","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation. J Exp Med. 2014;211:781\u201390.","journal-title":"J Exp Med"},{"key":"3635_CR54","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1073\/pnas.1417636112","volume":"112","author":"S Eikawa","year":"2015","unstructured":"Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA. 2015;112:1809\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3635_CR55","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-20-0113","volume":"26","author":"S Wang","year":"2020","unstructured":"Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, et al. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial. Clin Cancer Res. 2020;26:4921\u201332.","journal-title":"Clin Cancer Res"},{"key":"3635_CR56","doi-asserted-by":"publisher","first-page":"E341","DOI":"10.1152\/ajpendo.00346.2023","volume":"326","author":"X Zhang","year":"2024","unstructured":"Zhang X, Gao Y, Tang K, Li Z, Halberstam AA, Zhou L, et al. Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma. Am J Physiol Endocrinol Metab. 2024;326:E341\u2013E350.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"3635_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","volume":"5","author":"NE Scharping","year":"2017","unstructured":"Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res. 2017;5:9\u201316.","journal-title":"Cancer Immunol Res"},{"key":"3635_CR58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","volume":"6","author":"MZ Afzal","year":"2018","unstructured":"Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer. 2018;6:64.","journal-title":"J Immunother Cancer"},{"key":"3635_CR59","doi-asserted-by":"publisher","first-page":"e007235","DOI":"10.1136\/jitc-2023-007235","volume":"11","author":"M Akce","year":"2023","unstructured":"Akce M, Farran B, Switchenko JM, Rupji M, Kang S, Khalil L, et al. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer. J Immunother Cancer. 2023;11:e007235.","journal-title":"J Immunother Cancer"},{"key":"3635_CR60","doi-asserted-by":"crossref","unstructured":"Deng J, Jiang R, Meng E, Wu H. CXCL5: A coachman to drive cancer progression. Front Oncol. 2022;12:944494.","DOI":"10.3389\/fonc.2022.944494"},{"key":"3635_CR61","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1136\/gutjnl-2016-313075","volume":"66","author":"T Wang","year":"2017","unstructured":"Wang T, Zhao Y, Peng L, Chen N, Chen W, Lv Y, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017;66:1900\u201311.","journal-title":"Gut"},{"key":"3635_CR62","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","volume":"150","author":"SL Zhou","year":"2016","unstructured":"Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology. 2016;150:1646\u2013.e17.","journal-title":"Gastroenterology"},{"key":"3635_CR63","doi-asserted-by":"crossref","unstructured":"Vonderheide RH, Bear AS. Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer. Front Immunol. 2020;11:605619.","DOI":"10.3389\/fimmu.2020.605619"},{"key":"3635_CR64","doi-asserted-by":"publisher","first-page":"5884","DOI":"10.1073\/pnas.85.16.5884","volume":"85","author":"Y Shirayoshi","year":"1988","unstructured":"Shirayoshi Y, Burke PA, Appella E, Ozato K. Interferon-induced transcription of a major histocompatibility class I gene accompanies binding of inducible nuclear factors to the interferon consensus sequence. Proc Natl Acad Sci USA. 1988;85:5884\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3635_CR65","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03635-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:31:45Z","timestamp":1792582305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03635-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":65,"alternative-id":["3635"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03635-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HWMvL has received research funding and\/or medication supply from Amphera, Anocca, Astellas, AstraZeneca, Beigene, Boehringer, Daiichi-Sankyo, Dragonfly, MSD, Myeloid, ORCA, Servier. Has acted as a consultant\/advisor to: Auristone, Incyte, Merck, Myeloid, Servier, and as a speaker for: Astellas, Beigene, Benecke, BMS, Daiichi-Sankyo, JAAP, Medtalks, Novartis, Springer, Travel Congress Management B.V. NCTvG reports institutional consulting fees from Astellas, BMS, and MSD; and institutional payment of honoraria from Astellas and BMS. MFB has received research funding from Celgene, Frame Therapeutics, and Lead Pharma, and has acted as a consultant to Servier, Olympus and Wholomics. JG has a collaboration with Roche. TDdG owns shares in, and is a scientific advisor to, LAVA Therapeutics NV. SD reports a consultant or advisory role for BMS, research funding, medication supply, or both from Incyte, and speaker roles for Servier, BMS, and Benecke. Other authors report no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all patients. All tissues were collected as part of an IRB-approved biobank initiative which was approved by the Medical Ethics Committee of the VUmc (METC-VUmc identifier 2013.074) [8]. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}